Affiliation:
1. The Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford OX3 7FY, UK
2. Worthing Hospital, University Hospitals Sussex NHS Foundation Trust, Worthing BN11 2DH, UK
3. Formerly School of Health Sciences, Cardiff Metropolitan University, Cardiff CF5 2YB, UK
Abstract
It has been unequivocally established that kynurenic acid has a number of actions in a variety of cells and tissues, raising, in principle, the possibility of targeting its generation, metabolism or sites of action to manipulate those effects to a beneficial therapeutic end. However, many basic aspects of the biology of kynurenic acid remain unclear, potentially leading to some confusion and misinterpretations of data. They include questions of the source, generation, targets, enzyme expression, endogenous concentrations and sites of action. This essay is intended to raise and discuss many of these aspects as a source of reference for more balanced discussion. Those issues are followed by examples of situations in which modulating and correcting kynurenic acid production or activity could bring significant therapeutic benefit, including neurological and psychiatric conditions, inflammatory diseases and cell protection. More information is required to obtain a clear overall view of the pharmacological environment relevant to kynurenic acid, especially with respect to the active concentrations of kynurenine metabolites in vivo and changed levels in disease. The data and ideas presented here should permit a greater confidence in appreciating the sites of action and interaction of kynurenic acid under different local conditions and pathologies, enhancing our understanding of kynurenic acid itself and the many clinical conditions in which manipulating its pharmacology could be of clinical value.
Reference345 articles.
1. Induction of pulmonary indoleamine 2,3-dioxygenase by interferon;Yoshida;Proc. Natl. Acad. Sci. USA,1981
2. The Neuropharmacology of quinolinic and kynurenic acids;Stone;Pharmacol. Rev.,1993
3. Stone, T.W., Clanchy, F.I.L., Huang, Y.-S., Chiang, N.Y., Darlington, L.G., and Williams, R.O. (2022). An integrated cytokine and kynurenine network as the basis of neuroimmune communication. Front. Neurosci., 16.
4. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders;Stone;Brit. J. Pharmacol.,2013
5. Stone, T.W., and Williams, R.O. (2024). Tryptophan metabolism as a ‘reflex’ feature of neuroimmune communication: Sensor and effector functions for the indoleamine-2, 3-dioxygenase kynurenine pathway. J. Neurochem., in press.